Atea reports Q4 2022 net loss of $34.4M; provides clinical updates on COVID-19, HCV, and dengue programs

Atea Pharmaceuticals, Inc.

2022-FY EPS reported -$1.39

Net loss of $34.4M ($0.41 loss per share) in Q4 2022 vs net income of $117.1M in Q4 2021; full year 2022 net loss $115.9M.
Revenue $0 in Q4 and full year 2022 vs $192.2M and $351.4M in 2021 due to end of Roche collaboration.
Cash and marketable securities $646.7M at Dec 31, 2022, down from $764.4M at Dec 31, 2021.
Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 continues enrollment; interim analysis expected 2H23.
Dengue program deprioritized; Phase 2 HCV combination trial to start enrollment in 2Q23 with initial results by 4Q23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for Q4 and Full Year 2022.

Period: Q4 and Full Year 2022
Result: reported results

Exact text from the filing

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-053843

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.